24 May 2013 - GlaxoSmithKline, a global healthcare company, has collaborated with the Biomedical Advanced Research and Development Authority, a part of the US Department of Health and Human Services.

It is reported today that the collaboration is aimed at developing drugs against antibiotic resistance and bioterrorism. GSK antibacterial discovery performance unit head, David Payne, stated that new models are needed to deal with antibiotic resistance.

The project will receive funds through a public-private partnership. During the first 18 months, the US Department of Health and Human Services will provide USD40m and around USD200m upon the renewal over five years.